Chinese General Practice ›› 2023, Vol. 26 ›› Issue (24): 2997-3004.DOI: 10.12114/j.issn.1007-9572.2023.0029
Special Issue: 男性健康最新文章合集; 运动相关研究最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2022-12-19
Revised:
2023-03-16
Published:
2023-08-20
Online:
2023-04-03
Contact:
SUN Lixia
通讯作者:
孙丽霞
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0029
变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | 检验统计量值 | P值 |
---|---|---|---|---|---|---|---|
一般情况 | |||||||
年龄( | 36.9±7.7 | 34.9±7.8 | 35.4±7.4 | 37.2±7.2a | 40.1±7.3abc | 23.26d | <0.01 |
高脂血症〔例(%)〕 | 361(39.07) | 49(22.27) | 85(35.42) | 105(45.65) | 122(52.14)abc | 48.39 | <0.01 |
高血压〔例(%)〕 | 318(34.42) | 59(26.82) | 62(25.83) | 80(34.78) | 117(50.00)abc | 38.65 | <0.01 |
降压药史〔例(%)〕 | 92(9.96) | 11(5.00) | 16(6.67) | 23(10.00) | 42(17.95)abc | 25.60 | <0.01 |
饮酒史〔例(%)〕 | 519(56.17) | 117(53.18) | 126(52.50) | 135(58.70) | 141(60.26) | 4.29 | 0.23 |
吸烟史〔例(%)〕 | 566(61.26) | 143(65.00) | 146(60.83) | 143(62.17) | 134(57.26) | 2.97 | 0.40 |
体育锻炼〔例(%)〕 | 344(37.23) | 84(38.18) | 87(36.25) | 97(42.17) | 76(32.48) | 4.85 | 0.18 |
人体测量学指标 | |||||||
体质量( | 76.26±12.32 | 75.51±11.94 | 76.05±12.47 | 76.10±13.08 | 77.33±11.76 | 0.90d | 0.44 |
BMI( | 26.29±3.85 | 25.93±3.80 | 26.08±3.83 | 26.31±4.21 | 26.83±3.50 | 2.42d | 0.06 |
腰围( | 89.66±9.68 | 89.18±9.46 | 88.91±9.68 | 89.36±10.43 | 91.16±9.02 | 2.61d | 0.05 |
SBP( | 134±14 | 133±12 | 132±15 | 135±14 | 137±14ab | 6.42d | <0.01 |
DBP( | 85±12 | 84±12 | 84±12 | 85±13 | 88±10ab | 7.45d | <0.01 |
生化检测指标 | |||||||
空腹血糖〔M(P25,P75),mmol/L〕 | 5.40(5.00,5.82) | 4.74(4.50,4.88) | 5.20(5.10,5.30)a | 5.57(5.50,5.69)ab | 6.22(5.99,6.59)abc | 374.54e | <0.01 |
hs-CRP〔M(P25,P75),mg/L〕 | 0.24(0.01,1.40) | 1.19(0.30,2.60) | 0.25(0.01,1.70)a | 0.16(0.01,1.10)a | 0.11(0.01,0.36)ab | 115.97e | <0.01 |
三酰甘油〔M(P25,P75),mmol/L〕 | 1.23(0.83,1.95) | 1.00(0.75,1.59) | 1.19(0.80,1.84) | 1.32(0.84,2.12)a | 1.34(1.00,2.13)a | 23.33e | <0.01 |
总胆固醇( | 4.79±1.10 | 4.55±0.96 | 4.64±1.00 | 4.99±1.32ab | 4.96±1.03ab | 9.52d | <0.01 |
HDL-C( | 1.40±0.35 | 1.45±0.40 | 1.42±0.37 | 1.38±0.33 | 1.35±0.30a | 4.58d | <0.01 |
LDL-C( | 2.81±0.82 | 2.68±0.76 | 2.76±0.71 | 2.81±0.71 | 2.98±1.05ab | 5.22d | <0.01 |
Table 1 Comparison of epidemiological survey data of the subjects
变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | 检验统计量值 | P值 |
---|---|---|---|---|---|---|---|
一般情况 | |||||||
年龄( | 36.9±7.7 | 34.9±7.8 | 35.4±7.4 | 37.2±7.2a | 40.1±7.3abc | 23.26d | <0.01 |
高脂血症〔例(%)〕 | 361(39.07) | 49(22.27) | 85(35.42) | 105(45.65) | 122(52.14)abc | 48.39 | <0.01 |
高血压〔例(%)〕 | 318(34.42) | 59(26.82) | 62(25.83) | 80(34.78) | 117(50.00)abc | 38.65 | <0.01 |
降压药史〔例(%)〕 | 92(9.96) | 11(5.00) | 16(6.67) | 23(10.00) | 42(17.95)abc | 25.60 | <0.01 |
饮酒史〔例(%)〕 | 519(56.17) | 117(53.18) | 126(52.50) | 135(58.70) | 141(60.26) | 4.29 | 0.23 |
吸烟史〔例(%)〕 | 566(61.26) | 143(65.00) | 146(60.83) | 143(62.17) | 134(57.26) | 2.97 | 0.40 |
体育锻炼〔例(%)〕 | 344(37.23) | 84(38.18) | 87(36.25) | 97(42.17) | 76(32.48) | 4.85 | 0.18 |
人体测量学指标 | |||||||
体质量( | 76.26±12.32 | 75.51±11.94 | 76.05±12.47 | 76.10±13.08 | 77.33±11.76 | 0.90d | 0.44 |
BMI( | 26.29±3.85 | 25.93±3.80 | 26.08±3.83 | 26.31±4.21 | 26.83±3.50 | 2.42d | 0.06 |
腰围( | 89.66±9.68 | 89.18±9.46 | 88.91±9.68 | 89.36±10.43 | 91.16±9.02 | 2.61d | 0.05 |
SBP( | 134±14 | 133±12 | 132±15 | 135±14 | 137±14ab | 6.42d | <0.01 |
DBP( | 85±12 | 84±12 | 84±12 | 85±13 | 88±10ab | 7.45d | <0.01 |
生化检测指标 | |||||||
空腹血糖〔M(P25,P75),mmol/L〕 | 5.40(5.00,5.82) | 4.74(4.50,4.88) | 5.20(5.10,5.30)a | 5.57(5.50,5.69)ab | 6.22(5.99,6.59)abc | 374.54e | <0.01 |
hs-CRP〔M(P25,P75),mg/L〕 | 0.24(0.01,1.40) | 1.19(0.30,2.60) | 0.25(0.01,1.70)a | 0.16(0.01,1.10)a | 0.11(0.01,0.36)ab | 115.97e | <0.01 |
三酰甘油〔M(P25,P75),mmol/L〕 | 1.23(0.83,1.95) | 1.00(0.75,1.59) | 1.19(0.80,1.84) | 1.32(0.84,2.12)a | 1.34(1.00,2.13)a | 23.33e | <0.01 |
总胆固醇( | 4.79±1.10 | 4.55±0.96 | 4.64±1.00 | 4.99±1.32ab | 4.96±1.03ab | 9.52d | <0.01 |
HDL-C( | 1.40±0.35 | 1.45±0.40 | 1.42±0.37 | 1.38±0.33 | 1.35±0.30a | 4.58d | <0.01 |
LDL-C( | 2.81±0.82 | 2.68±0.76 | 2.76±0.71 | 2.81±0.71 | 2.98±1.05ab | 5.22d | <0.01 |
变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | F(H)值 | P值 |
---|---|---|---|---|---|---|---|
SBP1( | 132±15 | 130±14 | 131±15 | 132±16 | 135±16ab | 4.15 | <0.01 |
SBP2( | 132±15 | 130±14 | 132±15 | 132±15 | 135±15ab | 6.01 | <0.01 |
∆SBP〔M(P25,P75),mmHg〕 | 1(-5,6) | 0(-7,6) | 1(-4,6) | 0(-5,6) | 1(-5,7) | 4.54e | 0.21 |
DBP1( | 79±11 | 77±11 | 78±11 | 79±11 | 82±10ab | 8.04 | <0.01 |
DBP2( | 79±11 | 78±11 | 78±11 | 79±11 | 82±10abc | 9.62 | <0.01 |
∆DBP〔M(P25,P75),mmHg〕 | 0(-3,4) | 0(-3,4) | 0(-4,5) | 0(-3,4) | 1(-3,5) | 1.86e | 0.60 |
MAP1( | 99.17±12.50 | 97.23±12.19 | 98.03±12.24 | 99.28±13.03 | 102.04±12.08ab | 6.66 | <0.01 |
MAP2( | 99.44±11.98 | 97.57±11.14 | 98.74±12.14 | 99.39±12.10 | 101.97±12.10ab | 5.63 | <0.01 |
∆MAP〔M(P25,P75),mmHg〕 | 0.30(-4.20,5.10) | 0.80(-3.70,5.40) | 0.30(-3.80,5.50) | -0.05(-4.70,4.30) | -0.15(-4.50,4.90) | 1.70e | 0.64 |
HR1( | 80±13 | 80±12 | 79±12 | 81±12 | 81±12 | 2.14 | 0.09 |
HR2( | 86±14d | 85±13d | 85±14d | 85±12d | 87±14 | 1.34 | 0.26 |
∆HR〔M(P25,P75),次/min〕 | 5(0,10) | 6(0,11) | 5(0,11) | 4(-1,8) | 5(0,11) | 5.29e | 0.15 |
baPWV1( | 1 375.98±209.61 | 1 351.63±198.92 | 1 345.50±204.86 | 1 384.63±216.83 | 1 421.65±209.58abc | 6.63 | <0.01 |
baPWV2( | 1 342.24±208.82d | 1 309.95±194.19d | 1 312.10±208.65d | 1 343.84±203.35d | 1 401.92±215.65abcd | 10.08 | <0.01 |
∆baPWV〔M(P25,P75),cm/s〕 | -36.0 (-87.0,24.0) | -45.5 (-93.0,12.5) | -36.5 (-85.0,19.5) | -39.5 (-95.0,18.0) | -23.0 (-77.0,35.0) | 7.51e | 0.06 |
MET( | 12.16±2.55 | 12.42±2.78 | 12.21±2.26 | 12.22±2.78 | 11.79±2.33 | 2.49 | 0.06 |
VO2max( | 42.56±8.91 | 43.50±9.71 | 42.73±7.89 | 42.78±9.74 | 41.29±8.14 | 2.49 | 0.06 |
峰值HR( | 139.35±14.65 | 139.40±14.90 | 139.25±15.62 | 140.14±13.69 | 138.61±14.33 | 0.43 | 0.73 |
Time( | 7.13(4.94,11.16) | 7.51(5.41,11.37) | 7.38(4.92,12.61) | 7.03(5.00,11.15) | 6.67(4.73,9.55) | 8.22e | 0.06 |
Table 2 Comparison of baPWV-related data before and after the secondary load test of the power vehicle bicycle
变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | F(H)值 | P值 |
---|---|---|---|---|---|---|---|
SBP1( | 132±15 | 130±14 | 131±15 | 132±16 | 135±16ab | 4.15 | <0.01 |
SBP2( | 132±15 | 130±14 | 132±15 | 132±15 | 135±15ab | 6.01 | <0.01 |
∆SBP〔M(P25,P75),mmHg〕 | 1(-5,6) | 0(-7,6) | 1(-4,6) | 0(-5,6) | 1(-5,7) | 4.54e | 0.21 |
DBP1( | 79±11 | 77±11 | 78±11 | 79±11 | 82±10ab | 8.04 | <0.01 |
DBP2( | 79±11 | 78±11 | 78±11 | 79±11 | 82±10abc | 9.62 | <0.01 |
∆DBP〔M(P25,P75),mmHg〕 | 0(-3,4) | 0(-3,4) | 0(-4,5) | 0(-3,4) | 1(-3,5) | 1.86e | 0.60 |
MAP1( | 99.17±12.50 | 97.23±12.19 | 98.03±12.24 | 99.28±13.03 | 102.04±12.08ab | 6.66 | <0.01 |
MAP2( | 99.44±11.98 | 97.57±11.14 | 98.74±12.14 | 99.39±12.10 | 101.97±12.10ab | 5.63 | <0.01 |
∆MAP〔M(P25,P75),mmHg〕 | 0.30(-4.20,5.10) | 0.80(-3.70,5.40) | 0.30(-3.80,5.50) | -0.05(-4.70,4.30) | -0.15(-4.50,4.90) | 1.70e | 0.64 |
HR1( | 80±13 | 80±12 | 79±12 | 81±12 | 81±12 | 2.14 | 0.09 |
HR2( | 86±14d | 85±13d | 85±14d | 85±12d | 87±14 | 1.34 | 0.26 |
∆HR〔M(P25,P75),次/min〕 | 5(0,10) | 6(0,11) | 5(0,11) | 4(-1,8) | 5(0,11) | 5.29e | 0.15 |
baPWV1( | 1 375.98±209.61 | 1 351.63±198.92 | 1 345.50±204.86 | 1 384.63±216.83 | 1 421.65±209.58abc | 6.63 | <0.01 |
baPWV2( | 1 342.24±208.82d | 1 309.95±194.19d | 1 312.10±208.65d | 1 343.84±203.35d | 1 401.92±215.65abcd | 10.08 | <0.01 |
∆baPWV〔M(P25,P75),cm/s〕 | -36.0 (-87.0,24.0) | -45.5 (-93.0,12.5) | -36.5 (-85.0,19.5) | -39.5 (-95.0,18.0) | -23.0 (-77.0,35.0) | 7.51e | 0.06 |
MET( | 12.16±2.55 | 12.42±2.78 | 12.21±2.26 | 12.22±2.78 | 11.79±2.33 | 2.49 | 0.06 |
VO2max( | 42.56±8.91 | 43.50±9.71 | 42.73±7.89 | 42.78±9.74 | 41.29±8.14 | 2.49 | 0.06 |
峰值HR( | 139.35±14.65 | 139.40±14.90 | 139.25±15.62 | 140.14±13.69 | 138.61±14.33 | 0.43 | 0.73 |
Time( | 7.13(4.94,11.16) | 7.51(5.41,11.37) | 7.38(4.92,12.61) | 7.03(5.00,11.15) | 6.67(4.73,9.55) | 8.22e | 0.06 |
模型 | 自变量 | B(95%CI) | SE | t值 | P值 |
---|---|---|---|---|---|
模型1 | Q4 | ||||
Q1 | -30.10(-47.39,-12.82) | 8.81 | 6.66 | <0.01 | |
Q2 | -22.54(-39.48,-5.60) | 8.63 | -2.61 | 0.01 | |
Q3 | -25.38(-42.39,-8.37) | 8.67 | -2.93 | <0.01 | |
模型2 | Q4 | ||||
Q1 | -18.82(-36.69,-0.94) | 9.11 | -2.07 | 0.04 | |
Q2 | -12.71(-29.74,4.32) | 8.68 | -1.47 | 0.14 | |
Q3 | -19.58(-36.45,-2.71) | 8.60 | -2.28 | 0.02 | |
模型3 | Q4 | ||||
Q1 | -18.96(-36.96,-0.96) | 9.17 | -2.07 | 0.04 | |
Q2 | -12.37(-29.35,4.60) | 8.65 | -1.43 | 0.15 | |
Q3 | -15.23(-31.95,1.49) | 8.52 | -1.79 | 0.07 |
Table 3 Generalized linear model analysis of the effect of fasting blood glucose level on baPWV before and after the secondary load test of the power vehicle bicycle
模型 | 自变量 | B(95%CI) | SE | t值 | P值 |
---|---|---|---|---|---|
模型1 | Q4 | ||||
Q1 | -30.10(-47.39,-12.82) | 8.81 | 6.66 | <0.01 | |
Q2 | -22.54(-39.48,-5.60) | 8.63 | -2.61 | 0.01 | |
Q3 | -25.38(-42.39,-8.37) | 8.67 | -2.93 | <0.01 | |
模型2 | Q4 | ||||
Q1 | -18.82(-36.69,-0.94) | 9.11 | -2.07 | 0.04 | |
Q2 | -12.71(-29.74,4.32) | 8.68 | -1.47 | 0.14 | |
Q3 | -19.58(-36.45,-2.71) | 8.60 | -2.28 | 0.02 | |
模型3 | Q4 | ||||
Q1 | -18.96(-36.96,-0.96) | 9.17 | -2.07 | 0.04 | |
Q2 | -12.37(-29.35,4.60) | 8.65 | -1.43 | 0.15 | |
Q3 | -15.23(-31.95,1.49) | 8.52 | -1.79 | 0.07 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
韩旭,刘倩,马一涵,等. 非糖尿病人群空腹血糖水平对动脉僵硬度进展的影响[J]. 中华高血压杂志,2021,29(1):41-47. DOI:10.16439/j.issn.1673-7245.2021.01.010.
|
[19] |
|
[20] |
|
[21] |
|
[22] |
体育总局关于开展第五次国民体质监测的通知[EB/OL].(2019-02-02)[2022-08-02].
|
[23] |
|
[24] |
|
[25] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.
|
[26] |
中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35(5):390-419. DOI:10.3760/j.issn:0253-3758.2007.05.003.
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[1] | JIN Menglong, QIN Xiaoying, MALIYA Amiti, JIAZINI Nuerbai, LI Jianxin, CAO Jie, LUO Sifu, LIU Cheng, ZHANG Yuchen, GAI Mintao, LI Yanpeng, LU Xiangfeng, FU Zhenyan. Status and Influencing Factors of Dyslipidemia, Hypertension and Diabetes Comorbidities among Kazakhs in Xinjiang [J]. Chinese General Practice, 2024, 27(12): 1438-1444. |
[2] | SHI Weili, LI Mingyan, DUAN Hongyan. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Interpretation of the U.S. Preventive Services Task Force Recommendation Statement [J]. Chinese General Practice, 2024, 27(12): 1405-1412. |
[3] | LI Mingyan, SHI Weili, DUAN Hongyan. Aspirin Use to Prevent Cardiovascular Disease in Adults: Interpretation of U.S. Preventive Services Task Force Recommendations Statement [J]. Chinese General Practice, 2024, 27(11): 1277-1282. |
[4] | LIANG Dong, YANG Chenglin, LIN Xiaoru, ZHAO Yang, OUYANG Jiang, LIN Xiuquan. Burden of Cardiovascular Diseases Attributable to Diabetes among Chinese Adults from 1990 to 2019 [J]. Chinese General Practice, 2024, 27(11): 1380-1386. |
[5] | ZHANG Shengnan, XU Shihua, HUANG Rongchao, CHEN Jian, ZHAO Chunru, MENG Minglyu, MA Yingjiao. Trend and Forecast Analysis of Premature Mortality Probability by Four Major Non-communicable Diseases in Baise from 2015 to 2021 [J]. Chinese General Practice, 2024, 27(11): 1387-1394. |
[6] | XU Li, GE Jing, YU Peng, YU Ying. Shifts in Chronic Disease and Comorbidity Patterns among Chinese Older Adults: an Analysis Based on the China Health and Retirement Longitudinal Study [J]. Chinese General Practice, 2024, 27(11): 1296-1302. |
[7] | YU Xinyan, SU Peng, YUAN Xiaojing, JIANG Qingru, YANG Jianyun, ZHAO Xudong, WANG Yifan, ZHANG Haicheng. A Study on the Factors Influencing the Comprehensive Risk of Cardiovascular Disease in Elderly Patients with Chronic Disease in Primary Care [J]. Chinese General Practice, 2024, 27(10): 1186-1193. |
[8] | DAI Zhenwei, ZHANG Ling, ZHANG Haoran, XIAO Weijun, WANG Hao, HUANG Yiman, JING Shu, CHEN Xu, FU Jiaqi, WU Yijin, GAO Lei, SU Xiaoyou. Influencing Factors of Blood Glucose Monitoring in Middle-aged and Elderly Patients with Type-2 Diabetes Mellitus in Rural Areas [J]. Chinese General Practice, 2024, 27(10): 1194-1200. |
[9] | HAN Junjie, WU Di, CHEN Zhisheng, XIAO Yang, SEN Gan. A Nomogram Prediction Model and Validation Study on the Risk of Complicated Diabetic Nephropathy in Type 2 Diabetes Patients [J]. Chinese General Practice, 2024, 27(09): 1054-1061. |
[10] | HE Yufu, TONG Wenying, WANG Fang, LI Lixia, HE Junbing, SHAO Yiming. Effects of Pre-hospital Metformin Use on Clinical Outcomes in Patients with Diabetes and Sepsis [J]. Chinese General Practice, 2024, 27(09): 1034-1041. |
[11] | LI Ziyue, FANG Jiawen, LIN Kaicheng. Analysis and Prediction of the Disease Burden of Type 2 Diabetes Attributable to High Body Mass Index in China from 1990 to 2019 [J]. Chinese General Practice, 2024, 27(09): 1126-1133. |
[12] | ZOU Qiong, WU Xi, ZHANG Yang, WAN Yi, CHEN Changsheng. Prediction of Type 2 Diabetic Nephropathy Based on BP Neural Network Optimized by Sparrow Search Algorithm [J]. Chinese General Practice, 2024, 27(08): 961-970. |
[13] | GAO Yuan, ZHOU Min, QIN Manfen, XU Xuan, YANG Liping, FU Yahong, HUANG Ying, WANG Wei. Effects of Health Coaching Combined with Wearable Devices on Glucose and Lipid Metabolism and Self-management Behavior in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2024, 27(08): 908-914. |
[14] | ZHANG Jinyi, ZHANG Shizhong. Advances in Epidemiology and Related Mechanisms of Cardiovascular Diseases and Mental Illness [J]. Chinese General Practice, 2024, 27(08): 893-899. |
[15] | YAO Mi, LIN Kai, FAN Jieting, JI Xinxin, WANG Ying, DONG Aimei, HAN Xiaoning, QI Jianguang, CHI Chunhua, Haroon Shamil, Jackson Dawn, Cheng KK, Lehman Richard. Design and Development of Communication Skills Training in Diabetes Care for General Practitioners in China [J]. Chinese General Practice, 2024, 27(07): 816-821. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||